{"id":"W4415942047","doi":"10.1016/j.annonc.2025.08.1517","title":"948P Cancer Research UK first-in-human (FIH) phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 (HTL) as monotherapy and in combination with immunotherapy in patients with advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Antagonist; Immunotherapy; Blockade; Prostaglandin E2; Immune system; Receptor; Receptor antagonist; Cancer immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009273863,0.0009273748,0.001566397,0.000387408,0.0004307531,0.001005059,0.0006982144,0.001667204,0.0239912],"category_scores_gemma":[0.0007499529,0.0005997599,0.000984868,0.0003792715,0.0007068043,0.0005663872,0.0004426339,0.003431012,0.00287895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001031081,"about_ca_system_score_gemma":0.001605775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002447317,"about_ca_topic_score_gemma":0.008757964,"domain_scores_codex":[0.9996464,0.0001749877,0.00001033343,0.00004334605,0.00003155574,0.00009330781],"domain_scores_gemma":[0.9994872,0.00009157902,0.00006546287,0.00003614786,0.0000389496,0.0002807475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5053639,0.02189313,0.004274891,0.001948569,0.001959993,0.0008514651,0.000303863,0.002401042,0.07251349,0.001361776,0.0774769,0.3096509],"study_design_scores_gemma":[0.6141546,0.3037926,0.01448079,0.0002206414,0.0006882219,0.000594997,0.00009652887,0.0009300012,0.004560715,0.0006397738,0.05977979,0.00006145927],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9071386,0.02135725,0.001373168,0.01150657,0.001835336,0.00662143,0.01352618,0.0006122688,0.03602917],"genre_scores_gemma":[0.8943964,0.009613996,0.004300123,0.007925362,0.0007531916,0.003556265,0.01186154,0.0001706522,0.0674226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0239912,"threshold_uncertainty_score":0.08025855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02843056652631669,"score_gpt":0.4144217872121339,"score_spread":0.3859912206858171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}